Effect ofXuebijinginjection on the serum soluble CD40 ligand and lipoprotein associated phospholipase A2 of patients with acute coronary syndrome
10.3760/cma.j.issn.1673-4246.2016.06.006
- VernacularTitle:血必净对急性冠脉综合征患者血清可溶性CD40配体和脂蛋白相关性磷脂酶A2的影响
- Author:
Yajing ZHANG
;
Huikai ZHANG
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Soluble CD40 ligand;
Lipoprotein-phospholipase A2;
Xuebijinginjection;
Therapies,investigational
- From:
International Journal of Traditional Chinese Medicine
2016;38(6):504-507
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the effect ofXuebijing injection on the serum soluble CD40 ligand (soluble CD40 ligand, sCD40L), lipoprotein associated phospholipase A2 (lipoprotein-phospholipase A2, Lp-PLA2) of patients with acute coronary syndrome (ACS).Methods A total of 120 patients with ACS were randomized divided into the control group and treatment group, 60 in each group.The control group received the routine treatment of Western medicine, and the treatment group receivedXuebijing injectionbased on the intervention of control group. Both groups were treated for 2 weeks. ELISA method was used to detect serum sCD40L, Lp-PLA and IL-6, TNF-α and CRP.Results After treatment, the serum sCD40L(320.62 ± 35.81 pg/Lvs. 401.70 ± 4.84 pg/L, t=10.435), Lp-PLA2 (203.62 ± 33.13μg/L vs. 296.45 ± 4.422μg/L,t=12.831) level was significantly lower than those in the control group (P<0.01); The serum CRP (3.10 ± 2.00 mg/Lvs.4.74 ± 2.04 mg/L,t=4.006), IL-6 (2.10 ± 1.20 pg/Lvs.3.14 ± 1.40 pg/L,t=3.781), TNF (2.81 ± 1.50 pg/Lvs. 3.70 ± 1.70 pg/L,t=3.075) level was significantly lower than thosein the control group (P<0.01 orP<0.05). Compared with the control group, the effect rate (68.3%vs. 50.0%,χ2=4.174) of the treatment group was significantly higher (P=0.041).ConclusionXuebijing injection can improve the therapeutic effectof ACS patients, and reduce CD40L, Lp-PLA2 levels.
